Showing results (101-110 of 148) with videos related to
Sort By:
Pageof 15
The Journal of Rheumatology|February 1, 1991
Is the beneficial effect of sulfasalazine due to inhibition of synovial neovascularization?R Madhok, E Wijelath, J Smith, et al.Rheumatology (Oxford, England)|February 22, 2003
Rheumatoid arthritis and macrovascular diseaseJ K Alkaabi, M Ho, R Levison, et al.Scottish Medical Journal|May 5, 2012
Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled studyP Kumar, G Kennedy, F Khan, et al.British Journal of Clinical Pharmacology|September 1, 1991
The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of complianceT Pullar, S Kumar, H Chrystyn, et al.Rheumatology (Oxford, England)|June 27, 2001
Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritisA McEntegart, H A Capell, D Creran, et al.British Journal of Clinical Pharmacology|May 1, 1978
Continued use of non-steroidal anti-inflammatory drugs: an index of clinical efficacyP J Rooney, H A Capell, S Paterson, et al.British Journal of Rheumatology|October 1, 1988
The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapyT Pullar, S Peaker, M F Martin, et al.Rheumatology (Oxford, England)|October 16, 2001
Investigation of cutaneous microvascular activity and flare response in patients with fibromyalgia syndromeA W Al-Allaf, F Khan, J Moreland, et al.Clinical Pharmacology and Therapeutics|November 1, 1988
Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times dailyT Pullar, A J Birtwell, P G Wiles, et al.Current Medical Research and Opinion|January 1, 1976
Comparison of azapropazone and naproxen in rheumatoid arthritisH A Capell, M M McLeod, L A Hernández, et al.Pageof 15